Biotechnology News and Research

RSS

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

IMGM Labs purchases Fluidigm Access Array system to use in re-sequencing applications

IMGM Laboratories GmbH has purchased a Fluidigm Access Array System to use in its development and validation of targeted re-sequencing applications services.

16 Feb 2011

WaferGen offers SNP Genotyping screening with new SmartChip PCR System

WaferGen Biosystems, Inc. a leading developer of state-of-the-art genomic analysis systems, today announced that it is offering an early access program for high-throughput Single Nucleotide Polymorphism Genotyping through its new SmartChip Real-Time PCR System.

16 Feb 2011

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. reports that Advaxis, Inc. has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index.

16 Feb 2011

Sanofi-aventis enters definitive agreement to acquire Genzyme

Sanofi-aventis and Genzyme Corporation announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion.

16 Feb 2011

Fibrocell Science sells $7.8 million Series D convertible preferred stock

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that between December 8, 2010 and February 9, 2011 it entered into agreements with certain accredited investors, pursuant to which the Company sold to the purchasers in the aggregate approximately $7.8 million of the Company's Series D convertible preferred stock, which is convertible into shares of common stock at a conversion price of $0.50 per share.

16 Feb 2011

Partners, Luminex team up to discover novel biomarkers, develop clinical assays

Luminex Corporation announced today that it has teamed with Partners HealthCare toward the discovery of novel biomarkers and development of clinical assays.

From Luminex 16 Feb 2011

Bisphosphonates appear to reduce risk of postmenopausal colorectal cancer by 50%

An international team of researchers has found that the use of bisphosphonates - drugs already taken by millions of healthy women to prevent bone-loss - for more than one year was associated with a 50 percent reduction in the risk of postmenopausal colorectal cancer. The results were published this week in the Journal of Clinical Oncology.

15 Feb 2011

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Oncolytics Biotech Inc. today announced preliminary results from a U.S. Phase 2 clinical trial (REO 017) using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer. The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC).

15 Feb 2011

Evotec partners with ChemBridge to expand high throughput screening collection

Evotec AG today announced that it has entered into a collaboration with ChemBridge to further enhance its screening library. This collaboration demonstrates Evotec's continued improvement to its industry leading hit identification platform.

15 Feb 2011

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

PsychoGenics today announced the establishment of an alliance with KineMed, to provide specialized neurogenesis services to complement PsychoGenics' in vivo testing capabilities.

15 Feb 2011

Study shows lower success rate of FDA drug approval from 2003 to 2010

Biotechnology Industry Organization Industry Analysis and BioMedTracker announced results of a study today that shows the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10. Previous reports, taken from earlier years, showed the rate of drug approvals is one in five to one in six.

15 Feb 2011

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

Apricus Biosciences, Inc., announced today that it has entered into a licensing agreement granting Neopharm Group the exclusive rights to market and sell Vitaros®, Apricus Bio's treatment for erectile dysfunction ("ED") and, when and if available, its formulation for the treatment of premature ejaculation ("PE"), in Israel and the Palestinian Territories of the Gaza Strip and the West Bank.

15 Feb 2011

bioMD makes offer for Allied Medical

bioMD Limited (ASX: BOD), a company with assets in regenerative tissue engineering technologies today announced that it has made an offer to buy all of the shares in Allied Medical Limited (Allied), a public unlisted company that specialises in the sales, distribution and commercialisation of medical technologies.

14 Feb 2011

Microbix first quarter revenues decrease 34% to $812,694

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products, today reported financial results for the first quarter of fiscal 2011. For the quarter ended December 31, 2010, Microbix reported revenues of $812,694, a 34% decrease from $1,226,538 for the same period in 2009.

14 Feb 2011

Affymetrix introduces NG Class Detergents to advance study of integral membrane proteins

Affymetrix, Inc. today launched its Anatrace® brand Neopentyl Glycol (NG) Class™ Detergents, the next generation of detergents to significantly advance the study of integral membrane proteins (IMPs), the most important proteins found in the human genome.

14 Feb 2011

BioTime to merge Glycosan with OrthoCyte

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.

14 Feb 2011

Public-sector research has had an immediate effect on improving public health: Study

AUTM President Ashley Stevens, D. Phil. (Oxon), CLP is the lead author of The Role of Public Sector Research in the Discovery of Drugs and Vaccines, a paper published in the Feb. 10 issue of The New England Journal of Medicine.

14 Feb 2011

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fifth scheduled safety analysis and recommended that the trial continue per the protocol.

14 Feb 2011

Biotechnology News and Research

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

IMGM Labs purchases Fluidigm Access Array system to use in re-sequencing applications

WaferGen offers SNP Genotyping screening with new SmartChip PCR System

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Sanofi-aventis enters definitive agreement to acquire Genzyme

Fibrocell Science sells $7.8 million Series D convertible preferred stock

Partners, Luminex team up to discover novel biomarkers, develop clinical assays

Bisphosphonates appear to reduce risk of postmenopausal colorectal cancer by 50%

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Evotec partners with ChemBridge to expand high throughput screening collection

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

Study shows lower success rate of FDA drug approval from 2003 to 2010

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

bioMD makes offer for Allied Medical

Microbix first quarter revenues decrease 34% to $812,694

Affymetrix introduces NG Class Detergents to advance study of integral membrane proteins

BioTime to merge Glycosan with OrthoCyte

Public-sector research has had an immediate effect on improving public health: Study

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News